Market Take: Boston Life Sciences Real Estate Shows Improving Momentum

Greater Boston’s lab and life sciences property market is still working through elevated vacancy and oversupply, but major tenant commitments, stronger funding activity, and new manufacturing investment are pointing toward a gradual recovery.

"340B is going away." People have said that for 30 years. VytlOne's CEO explains why they keep being wrong.

Kim Tzoumakas came to pharmacy after two decades as a healthcare lawyer. Her core argument: 340B isn't a loophole or a relic. It's infrastructure. Here's how that belief shapes the way she builds product, runs a CFO conversation, and draws the line on AI.

#536 - Is 340B really going away — or finally becoming infrastructure? | Kim Tzoumakas (CEO, VytlOne)

One drug. Five specialties. Nobody coordinating.

How GLP-1s broke the point-solution model, and why coordination is becoming the moat. With Mark Clermont and Wendi Mader of Cecelia Health.

#535 - Why is chronic disease still winning? | Mark Clermont (CEO, Cecelia Health) & Wendi Mader (CCO)

A decade of "fixing" healthcare. Here's what everyone missed.

Cotiviti's new CEO thinks the whole industry has been misdiagnosing the trillion-dollar problem.

Midjourney Medical: What We Know So Far About the AI Company’s Full-Body Ultrasound Scanner

#534 - Can Cotiviti build the infrastructure layer healthcare's never had? | Ric Sinclair (CEO, Cotiviti)

Inside the Hidden Machinery of Healthcare Payments

Why MedEvolve Is Fixing What No One Sees

OnMed’s Karthik Ganesh Wants to Fix the Front Door of Healthcare

Xealth Wants Healthcare to Reach Patients Before Google Does

From the DMV to the Mayo Clinic

How Medecision and Excell Are Humanizing Healthcare

Tenant Leverage Grows in Life Sciences Real Estate

How Lease Strategy Turned a R&D Site Into a Strategic Win

Reinventing the Clinical Note

How Pieces and SmarterDx Are Changing the Game